Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming

Chimeric antigen receptor T (CAR T) cells targeting CD19 have achieved breakthroughs in the treatment of haematological malignancies, but many clinical studies have also shown that a proportion of patients relapse after remission.In this study, we designed CART treatment by DNMTi?dCART) inhibitor and found that dCAR T cells retained relatively potent antitumour activity compared with CAR T cell upon target antigen recognition. It may be associated with memory and anti-exhausion. Our transcriptional analysis underscores the potential of dCAR T cells. Overall design: In order to assess the different phenotypic and functional patterns of CARs between dCAR T and CAR T, we compared the genome-wide transcriptional profiles of dCAR and CAR T cell before and after cocultured with Raji cells for 24 h.